- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05825274
TDC'er til behandling af lægemiddelresistent epilepsi
Transkraniel jævnstrømsestimulering til behandling af lægemiddelresistent epilepsi hos børn
Epilepsy is the fourth overall neurologic disorder, regardless of age and gender, affecting more than 50 million people worldwide. Modern epidemiological studies indicate that the global annualized cumulative incidence ranges between 42.8 and 67.8 new cases per 100,000 people each year, with figures scaling up to 139 per 100,000 in low- and middle-income regions. A community-based study conducted in France concluded that up to 22.5% of patients could be classified as presenting drug-resistant epilepsy. This group presents significant hazards such as an increased risk of death, injuries, psychosocial dysfunction, and a reduced quality of life.
Studieoversigt
Status
Betingelser
Intervention / Behandling
Detaljeret beskrivelse
The International League Against Epilepsy (ILAE) defines drug-resistant epilepsy as follows: A failure of adequate trials of two (or more) tolerated, appropriately chosen, appropriately used antiepileptic drugs (whether administered as monotherapies or in a combination) to achieve freedom from seizures. This significant amount of patients is the drive to develop different approaches in order to offer alternatives for control.In this regard, non-invasive brain stimulation protocols lead the way, since the pathophysiological substrate of epilepsy is an enhanced cortical excitability, leading to paroxysmal depolarization shifts, an enhanced probability of high-frequency and hypersynchronous activity of small neuronal networks, and the abnormal spreading of this pathological activity along cortico-cortical and cortico-subcortical neuronal connections.Transcranial direct current stimulation (tDCS) consists of short-lasting electric stimulus delivered to specific brain regions. When delivered repeatedly, it generates long-lasting cortical excitability shifts through mechanisms resembling long-term depression (LTD). In this study, cathodal tDCS (c-tDCS) is utilized to apply a hyperpolarizing current directly over the primary epileptogenic focus, aiming to suppress pathological network activity and reduce seizure frequency in pediatric patients.
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Ikke anvendelig
Kontakter og lokationer
Studiesteder
-
-
Merseyside
-
Liverpool, Merseyside, Det Forenede Kongerige, L1 0AH
- Bigdata4brain LTD
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Inclusion Criteria:
- Pediatric patients aged between 4 and 6 years at the time of screening.
- Formally diagnosed with drug-resistant focal epilepsy according to the International League Against Epilepsy (ILAE) criteria (failure of adequate trials of two or more tolerated, appropriately chosen, and appropriately used antiepileptic drug regimens).
- Experiencing a baseline frequency of at least 3 clinical seizures per week, documented via a reliable prospective seizure diary kept by parents or caregivers.
- Patients whose legal guardians are willing and able to provide written informed consent, and patients who can provide assent when age-appropriate.
Exclusion Criteria:
- Presence of metallic implants in the brain or skull (e.g., surgical clips, cochlear implants) near the site of electrode placement.
- History of severe cardiac arrhythmias, unstable cardiovascular disease, or baseline pacemaker dependent, which may compromise safety during Heart Rate Variability (HRV) monitoring.
- Progressive neurological disorders, neurodegenerative diseases, or active brain tumors.
- Recent changes in antiepileptic drug (AED) dosages or types within the 4 weeks prior to baseline screening.
- Any active skin lesions, inflammation, or structural cranial abnormalities at the target electrode site that prevent safe application of the tDCS pads.
- Current participation in another clinical trial involving investigational drugs or neurostimulation devices.
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Randomiseret
- Interventionel model: Parallel tildeling
- Maskning: Firedobbelt
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Experimental: Active c-tDCS Group
A cohort of 50 pediatric patients with drug-resistant focal epilepsy experiencing at least 3 seizures per week. Participants receive active cathodal transcranial direct current stimulation (c-tDCS) targeted over the primary epileptogenic focus. Digital electroencephalography (EEG) utilizing a 19-channel montage is performed immediately before and after the intervention period. Treatment efficacy on psychosocial outcomes is evaluated using the Quality of Life in Epilepsy Inventory for Adolescents/Children (QOLIE-31) questionnaire. |
Active cathodal stimulation delivered at twice-weekly intervals. Each therapeutic session lasts 30 minutes, with the cathode electrode localized over the patient-specific epileptic focus to reduce cortical hyperexcitability.
Andre navne:
|
|
Eksperimentel: Device: Active Cathodal tDCS
Active cathodal stimulation delivered at twice-weekly intervals. Each therapeutic session lasts 35 minutes, with the cathode electrode localized over the patient-specific epileptic focus to reduce cortical hyperexcitability. |
Active cathodal stimulation delivered at twice-weekly intervals. Each therapeutic session lasts 30 minutes, with the cathode electrode localized over the patient-specific epileptic focus to reduce cortical hyperexcitability.
Andre navne:
|
|
Sham-komparator: : Placebo Comparator: Sham tDCS Group
A control cohort of 50 pediatric patients with drug-resistant focal epilepsy experiencing at least 3 seizures per week. Participants undergo the identical procedural, preparation, and 19-channel EEG monitoring protocols before and after the intervention as the experimental group, but receive inactive sham (placebo) stimulation. Quality of life tracking is assessed via the QOLIE-31 questionnaire. |
Active cathodal stimulation delivered at twice-weekly intervals. Each therapeutic session lasts 30 minutes, with the cathode electrode localized over the patient-specific epileptic focus to reduce cortical hyperexcitability.
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Weekly Seizure Frequency
Tidsramme: Baseline and Week 24
|
Assessment of patient-reported quality of life. The total score ranges from 0 to 100 points, where higher scores indicate a better quality of life. This scale will be evaluated as a single independent outcome measure. BaselineF LIFE IN EPILEPSY - QOLIE-31. |
Baseline and Week 24
|
|
Heart Rate Variability (HRV) Changes
Tidsramme: Baseline and Week 24
|
To evaluate cardiac safety, specific parameters will be extracted and analyzed from standard 12-lead ECG recordings. The assessed components will explicitly include: Heart Rate (bpm), PR interval (ms), QRS complex duration (ms), QT interval (ms), and corrected QT interval (QTc, ms) using Fridericia's formula |
Baseline and Week 24
|
|
Change from Baseline in Seizure Frequency
Tidsramme: Baseline and Week 24
|
Evaluation of efficacy based on the change in seizure frequency. This metric will assess the number of observable seizures per 28-day period (seizures/28 days), as documented by patient/caregiver diaries, comparing the baseline phase to the final 4 weeks of the treatment period (up to Week 24). |
Baseline and Week 24
|
|
Change from Baseline in Vital Signs
Tidsramme: Baseline and Week 24
|
Evaluation of clinical safety through the assessment of vital signs. The specific metrics to be evaluated independently as continuous variables include: Systolic Blood Pressure (mmHg), Diastolic Blood Pressure (mmHg), Heart Rate (beats per minute), and Body Temperature (°C). |
Baseline and Week 24
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Brain Electrical Activity via Electroencephalogram (EEG)
Tidsramme: Baseline and Week 24
|
Neurophysiological changes and treatment efficacy will be quantified using quantitative EEG (qEEG) analysis. The evaluation will precisely assess changes in absolute and relative power spectral density across the following frequency bandwidths: Delta (0.5-4 Hz), Theta (4-8 Hz), Alpha (8-12 Hz), and Beta (12-30 Hz). Additionally, the hourly frequency of epileptiform discharges (spikes and sharp waves) will be quantified to assess seizure susceptibility. |
Baseline and Week 24
|
Andre resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Kessler Foundation Neglect Assessment Process
Tidsramme: 4 Months
|
During each assessment session, occupational therapists measured patients' functions with the KF-NAP, Functional Independence Measure (FIM™) and Barthel Index (BI) |
4 Months
|
Samarbejdspartnere og efterforskere
Efterforskere
- Studiestol: Fernando Vargas Torgal, MD, FSI, Fundacion Salud Infantil Elxe (Alcante)
Publikationer og nyttige links
Generelle publikationer
- Varga ET, Terney D, Atkins MD, Nikanorova M, Jeppesen DS, Uldall P, Hjalgrim H, Beniczky S. Transcranial direct current stimulation in refractory continuous spikes and waves during slow sleep: a controlled study. Epilepsy Res. 2011 Nov;97(1-2):142-5. doi: 10.1016/j.eplepsyres.2011.07.016. Epub 2011 Aug 31.
- Strzelczyk A, Griebel C, Lux W, Rosenow F, Reese JP. The Burden of Severely Drug-Refractory Epilepsy: A Comparative Longitudinal Evaluation of Mortality, Morbidity, Resource Use, and Cost Using German Health Insurance Data. Front Neurol. 2017 Dec 22;8:712. doi: 10.3389/fneur.2017.00712. eCollection 2017.
- Engel J Jr. Approaches to refractory epilepsy. Ann Indian Acad Neurol. 2014 Mar;17(Suppl 1):S12-7. doi: 10.4103/0972-2327.128644.
- Cao Y, Cheung NA, Giustini D, LeDue J, Murphy TH. Scholar Metrics Scraper (SMS): automated retrieval of citation and author data. Front Res Metr Anal. 2024 Feb 22;9:1335454. doi: 10.3389/frma.2024.1335454. eCollection 2024.
- Ricci FS, D'Alessandro R, Soma A, Salvalaggio A, Rossi F, Rampone S, Gamberini G, Davico C, Peretta P, Cacciacarne M, Gaglini P, Pacca P, Pilloni G, Ragazzi P, Bertin D, Vallero SG, Fagioli F, Vitiello B. Development and application of a diagnostic and severity scale to grade post-operative pediatric cerebellar mutism syndrome. Eur J Pediatr. 2022 Mar;181(3):941-950. doi: 10.1007/s00431-021-04290-x. Epub 2021 Oct 14.
- Estrin S, Hu Y, Shapiro D, Zhang P. Agglomeration costs limit sustainable innovation in cities in developing economies. PLoS One. 2024 Nov 14;19(11):e0308742. doi: 10.1371/journal.pone.0308742. eCollection 2024.
- Sandesara UN. The narrative governance of life: Morality, melodrama, and the limits of biopower in western Indian efforts against sex selection. Med Anthropol Q. 2025 Jun;39(2):e12901. doi: 10.1111/maq.12901. Epub 2024 Nov 29.
- van der Groen O, Latella C, Nosaka K, Edwards D, Teo WP, Taylor JL. Corticospinal and intracortical responses from both motor cortices following unilateral concentric versus eccentric contractions. Eur J Neurosci. 2023 Feb;57(4):619-632. doi: 10.1111/ejn.15897. Epub 2023 Jan 17.
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Faktiske)
Studieafslutning (Faktiske)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Hjernesygdomme
- Sygdomme i centralnervesystemet
- Sygdomme i nervesystemet
- Epilepsi
- Lægemiddelresistent epilepsi
- Terapeutik
- Adfærdsdiscipliner og aktiviteter
- Elektrisk stimuleringsterapi
- Kvulterende terapi
- Psykiatriske somatiske terapier
- Elektroshock
- Psykologiske teknikker
- Transkraniel jævnstrømstimulering
Andre undersøgelses-id-numre
- RefEpTDCs
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
biogdata4brain.com is the database where our foundation recorda all the clinical data of our assays
IPD-delingstidsramme
4 Months
IPD-delingsadgangskriterier
login and password previous registration in neuroterapias.es
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .